MET and glioblastoma: Capmatinib is one of the few selective c-Met inhibitors to enter clinical trials for glioblastoma, but had little clinical activity in PTEN-deficient recurrent glioblastoma patients.240 Clinical trials of the combination of capmatinib and bevacizumab are currently underway in glioblastoma patients (NCT02386826).